The company will work with USC researchers in a year-long study aimed at assessing the clinical utility of EntroGen's PCR-based liquid biopsy test for EGFR mutations.
The test is a targeted next-gen sequencing assay that uses Illumina's MiniSeq, MiSeq, and NextSeq platforms to detect somatic mutations in BRCA1 and BRCA2.
EntroGen this week announced the availability of expanded colorectal cancer screening products.
Myriad Releases Interim PROCEDE 500 Clinical Utility Trial Data for Prolaris
The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.